ACELYRIN, INC. to Participate in Upcoming Investor Conferences

Rhea-AI Summary

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focusing on immunology, has announced its participation in three upcoming investor conferences in September 2024. The company's management team will engage in fireside chats and one-on-one meetings at the following events:

• Wells Fargo Healthcare Conference in Boston on September 5
• Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 6
• H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9

Live webcasts of the fireside chats will be available on ACELYRIN's website, with replays accessible for 30 days after each event.

LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that members of its management team will participate in fireside chats and 1x1 meetings at the following investor conferences:

Wells Fargo Healthcare Conference 2024
Date: Thursday, September 5, 2024
Location: Boston, MA
Fireside chat: 1:30 PM - 2:05 PM ET

Morgan Stanley 22^nd Annual Global Healthcare Conference
Date: Friday, September 6, 2024
Location: New York, NY
Fireside chat: 11:30 AM - 12:05 PM ET

H.C. Wainwright 26^th Annual Global Investment Conference
Date: Monday, September 9, 2024
Location: New York, NY
Fireside chat: 2:00 PM - 2:30 PM ET

Live webcasts of the fireside chats will be available on the Company’s website under Events & Presentations. Replays of each webcast will be available on the Company’s website for 30 days following the event.

About ACELYRIN, INC.
ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN’s lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.

For more information about ACELYRIN, visit us at www.acelyrin.com or follow us on LinkedIn and X.

Forward Looking Statements
Some statements in this press release are, or may be considered, forward-looking statements, including statements regarding ACELYRIN’s business plans and potential future benefits of our pipeline. While ACELYRIN, INC. considers any projections to be based on reasonable assumptions, these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated in such forward-looking statements.

ACELYRIN Contacts:
Tyler Marciniak
Vice President of Investor Relations and Corporate Affairs
investors@acelyrin.com
media@acelyrin.com

FAQ

What investor conferences will ACELYRIN (SLRN) attend in September 2024?

ACELYRIN (SLRN) will participate in three investor conferences in September 2024: Wells Fargo Healthcare Conference on September 5, Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, and H.C. Wainwright 26th Annual Global Investment Conference on September 9.

Where can investors watch ACELYRIN's (SLRN) fireside chats from the September 2024 conferences?

Investors can watch live webcasts of ACELYRIN's (SLRN) fireside chats on the company's website under the Events & Presentations section. Replays will be available for 30 days following each event.

What is the focus of ACELYRIN (SLRN) as a biopharma company?

ACELYRIN (SLRN) is a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology.

When and where will ACELYRIN (SLRN) participate in the Wells Fargo Healthcare Conference 2024?

ACELYRIN (SLRN) will participate in the Wells Fargo Healthcare Conference 2024 on Thursday, September 5, 2024, in Boston, MA. Their fireside chat is scheduled for 1:30 PM - 2:05 PM ET.